All Companies articles – Page 11
-
ArticleAI at the forefront of age-related disease treatment
The body undergoes changes with age that can lead to conditions like sarcopenia and osteoarthritis, burdening individuals and healthcare systems. Find out how Rejuvenate Biomed uses AI to decode ageing biology and develop combination therapies targeting the root causes of age-related diseases, offering hope for better treatments and quality of ...
-
NewsK Navigator: an AI co-pilot transforming biomedical research
K Navigator, a new AI-powered research co-pilot, is set to transform biomedical science by helping researchers explore complex data and accelerate discoveries.
-
News
New data: Visugromab targets ADC resistance mechanism
CatalYm announces new preclinical data showing that its clinical-stage antibody, visugromab, can overcome resistance to antibody-drug conjugates (ADCs), showing potential to restore anti-tumour immune responses in solid tumours.
-
News
Enedra secures funding to advance AI-driven cancer platform
Enedra Therapeutics has secured new funding to advance its AI-driven CASPAROV platform, aimed at developing therapies for difficult-to-treat cancers
-
ArticleHow AI and LLMs are transforming drug discovery: part 1
AI is reshaping drug discovery – but not without resistance. In this two-part conversation, André França and Eli Pollock share honest insights about the real barriers to AI adoption in life sciences and how embedding domain expertise into AI workflows might be the key to unlocking its full potential.
-
ArticleCracking the code to scalable cell and gene therapy
Cell and gene therapy is rapidly transforming the treatment of complex diseases, yet scaling production efficiently remains a challenge. Dr Tia Harmon from PHC Corporation of North America explores the innovations that are optimising cell expansion to enhance the discovery of advanced therapies.
-
NewsEli Lilly backs Creyon’s quantum chemistry platform in $1B RNA drug deal
The partnership allows for the further development of AI-designed RNA-targeted therapies for a range of diseases.
-
ArticleOptimising analytical strategies for ADC development
Antibody-drug conjugates (ADCs) are transforming cancer therapy by enabling targeted drug delivery with minimised side effects, but their complex structure presents unique challenges in bioanalysis. This article explores cutting-edge strategies for optimising ADC evaluation, from quantifying drug-to-antibody ratios (DAR) to overcoming hurdles like payload interference and stability.
-
ArticleAACR 2025: translating research into real-world impact
From first-in-human trial results to emerging AI tools and patient-focused innovations, AACR 2025 offered a clear snapshot of where cancer research is heading. Drug Target Review was on the ground in Chicago to explore the clinical data, technologies, and conversations shaping cancer drug development.
-
ArticleBuilding the requisite clinical development infrastructure for medical innovation to thrive
Outdated clinical development systems are slowing breakthroughs like gene therapies and precision medicine. This article explores how a flexible, on-demand approach can accelerate drug development and bring innovations to patients faster.
-
ArticleAI in drug discovery: faster, smarter, better
Claudia Zylberberg, Chair of Kosten Digital, reveals how AI is revolutionising cell and gene therapy, making drug discovery faster and more cost-effective.
-
ArticleUsing knowledge graphs in drug discovery (Part 2): how they’re shaping scientific progress
In this second interview of the series, Andreas Kolleger, Head of GenAI Innovation at Neo4j, discusses how knowledge graphs and AI are transforming scientific discovery and improving life sciences workflows.
-
ReportBeyond the Lab: Clinical Trials
Explore how artificial intelligence (AI), biomarkers, and innovative trial technologies are creating a more efficient, data-driven future for drug discovery. From better patient selection to smarter trial design, see how clinical research is evolving to deliver new therapies faster.
-
ArticleBuilding better drugs: how 3D models are shaping pre-clinical development
Three-dimensional (3D) models are reshaping pre-clinical drug development by providing more accurate insights into drug safety and efficacy. Explore how these advanced in vitro systems help improve predictions and reduce the risk of failure in early-stage drug discovery.
-
ArticleNext-gen ADCs: Tubulis sets new standard in cancer treatment
Tubulis, led by CEO Dominik Schumacher, is advancing cancer treatment through next-generation antibody-drug conjugates (ADCs) designed to target solid tumours more effectively. Find out how the company is rapidly progressing its ADC pipeline to offer more precise and lasting treatment options for patients.
-
ArticleAI-powered imaging for faster lung disease treatment
Deep learning is transforming lung disease treatment by enabling earlier diagnosis, precise monitoring and more efficient clinical trials. This article explores how AI-driven imaging is accelerating drug development and improving patient outcomes.
-
ArticleLB-102: Redefining schizophrenia treatment in drug discovery
Find out how LB Pharmaceuticals' LB-102 is advancing schizophrenia treatment. This first-in-class antipsychotic demonstrates strong efficacy, safety and tolerability, potentially addressing both acute and negative symptoms. Explore its potential impact on neuropsychiatric drug discovery.
-
ArticlePioneering cellular therapies for age-related diseases
Discover how Immorta Bio's cellular therapies are addressing cancer and liver failure, with the potential to transform healthcare.
-
NewsBacteria-boosted nanoparticles offer a triple threat against cancer
A new cancer therapy combines multiple treatment strategies into a single graphene oxide-based nanocomposite. It uses bacterial components to enhance immune response and scalability, creating a powerful and cost-effective approach to tackling tumours.
-
NewsNew leadership at ELRIG aims to expand collaboration across drug discovery
ELRIG, a UK-based scientific community driving innovation in drug discovery, has appointed biopharma leader Dr Del Trezise as its new Chair - signalling a bold new chapter for the organisation.